Social Media in the Pharmaceutical Industry Conference 2019

SMi Group21 - 23 January 2019, London, UK.
SMi Group are delighted to present the return of their 11th annual Social Media in the Pharmaceutical Industry conference to London on the 21st - 23rd January 2019. Social media is the perfect channel for pharmaceutical companies to educate, market, listen and connect with customers, patients and physicians. How the pharmaceutical industry utilize social media is particularly complex as regulators such as the FDA have not yet written the rules about how pharmaceuticals can engage with potential customers and patients.

Join SMi's 11th annual Social Media in the Pharmaceutical Industry conference to learn the best way your company can benefit from a robust social media strategy. Hear from industry experts on how to leverage social media platforms by keeping the patient at the forefront and exploring the latest advances in digital application such as Artificial Intelligence, challenges and techniques in the field of 'social pharma'.

How Will You Benefit?

Network and learn from leading professionals such as:

  • [Chair] Jason Browning, Global Head of Digital Communications & Social Media, Novartis
  • [Chair] Emma Sutcliffe, Director Patient Engagement and Innovation, NexGen Healthcare Communications
  • Roeland Van der Heiden, Digital Director, AstraZeneca
  • Lin Lei, Associate Director Digital Customer Engagement, Teva
  • Joao Bocas, CEO, DigitalSalutem
  • Paul Tunnah, CEO, PharmaPhorumMedia
  • Jacob D Flindt, Founder, InforMed.pro
  • Alan Shaw, Director, Strategic Planet; Senior Lecturer: Digital Marketing, Northumbria University
  • Dennis Fink, Campaign Manager and Social Media Channel Expert, Qiagen
  • Stefania Alvino, Multichannel Manager, Daiichi Sankyo Co., Ltd.

2019 Featured Highlights

  • Explore a result driven, value focused social media strategy in the pharmaceutical industry
  • Gain insight into procedures and practices required prior to the implementation of social listening
  • Discuss how to personalise the content relationships with AI
  • Understand the optimisation of disease awareness through social media channels
  • Learn how to use social networks and digital communication to engage HCPs
  • GDPR regulations and limitations to product advertisement (with case studies)
  • Pharmacovigilance in social media - specifically in adverse events reporting

For further information and to register, please visit:
http://www.social-media-pharma.com/wpn

Early-Bird Rates

  • Register by 29th September and save £400
  • Register by 31st October and save £200
  • Register by 30th November and save £100

About SMi Group
The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...